SUFFERN,
N.Y., Sept. 17, 2024 /PRNewswire/ -- Building on
recent clinical data, CDx Diagnostics today presented expert
testimony underscoring the profound impact of WATS3D
(Wide-Area Transepithelial Sampling with 3D Analysis) on patient
care and further demonstrating its crucial role in the management
of Barrett's esophagus (BE) and dysplasia.
With significantly enhanced detection
rates, WATS3D empowers physicians to implement timely and targeted
interventions.
"While the detection rate improvements are compelling, the human
impact really drives home the importance of this technology," said
Dr. Matthew J. McKinley of NYU
Langone.
"One in five of our patients would have likely remained unaware
of their Barrett's esophagus - a precancerous condition with a
small but real risk of progressing to an esophageal cancer that has
an abysmal 20% five-year survival rate. Now we can potentially
monitor patients closely and take preventative measures before
their disease potentially advances to a much more serious level
with a dire outlook."
With significantly enhanced detection rates, WATS3D
empowers physicians to implement timely and targeted interventions,
leading to better long-term patient outcomes. These findings,
detailed in a recent study, translate to significant real-world
impact on patient care.
The recent study Adjunctive Use of WATS-3D In Symptomatic GERD
Patients Increases Detection of Barrett's Esophagus and Dysplasia
in The American Journal of Gastroenterology highlights the
superior detection capabilities of WATS3D. The study
found 20% more BE cases and 2x the number of dysplasia diagnoses
compared to traditional methods. Also notable was that in 91% of
cases with conflicting forceps results, patient care favored the
WATS diagnosis, demonstrating the impact of WATS3D in
clinical decision-making.
"CDx Diagnostics has processed over 400,000 WATS3D
patient samples and has 23 published studies supporting its
efficacy, making it a game-changer in esophageal precancer
detection. With WATS3D integrated into routine practice,
healthcare providers can offer superior care and peace of mind to
their patients," says Tom Bartel,
Executive Vice President of Sales at CDx Diagnostics.
For more information about WATS3D and its benefits,
please visit www.cdxdiagnostics.com or email us at
WATS3D@cdxdiagnostics.com.
About CDx Diagnostics
CDx Diagnostics is driven by its mission to Empower
Physicians with Innovative Technology to Prevent Esophageal Cancer,
One Patient at a Time. The
company's proprietary diagnostic platform combines advanced
computer imaging, artificial intelligence, molecular biology, and
3D cytopathology to detect precancerous changes earlier and with
greater precision than conventional methods. By addressing a
critical gap in the current diagnostic standard of care, CDx's
pioneering solutions have enabled the early detection of thousands
of cancers and precancerous conditions, unlocking opportunities for
timely and effective treatment.
View original
content:https://www.prnewswire.com/news-releases/wats3d-revolutionizes-barretts-esophagus-management-with-unprecedented-early-detection-rates-leading-to-better-patient-outcomes-302250442.html
SOURCE CDx Diagnostics